Senior MiMedx execs heading to Craig-Hallum investor event
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN. Interested institutional investors can request meetings with management through their Craig-Hallum representatives to discuss the company's strategies and recent performance. This participation follows a period of mixed signals for MiMedx, including product launches and cost-reduction efforts alongside a reduction in Q1 2026 sales guidance.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP has announced an investigation into MiMedx Group, Inc. (NASDAQ: MDXG) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after MiMedx reported disappointing Q1 2026 financial results, missing consensus estimates for both earnings per share and revenue. The company attributed the poor performance to new Medicare reimbursement policies affecting the advanced wound care space, leading to a decrease in its full-year net sales expectations.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, in Minneapolis, MN. Investors are invited to contact their Craig-Hallum representative for meetings. MIMEDX specializes in healing solutions, particularly for chronic wounds, burns, and surgical applications.
MiMedx Group stock (US60251E1029): earnings turnaround and wound-care demand in focus
MiMedx Group has achieved profitability and raised its 2025 outlook, attracting investor attention to its regenerative wound-care business. The company focuses on placental tissue products for chronic wounds in US hospital and outpatient settings, navigating a competitive market with an evidence-driven differentiation strategy. Investors are watching its ability to sustain growth, manage regulatory demands, and adapt to healthcare policy changes.
MiMedx Group (MDXG) price target decreased by 18.75% to 6.63
This article reports that the price target for MiMedx Group (MDXG) has been decreased by 18.75%, bringing it down to $6.63. The specific reasons or analyst behind this adjustment are not detailed in this brief excerpt.
About Us | Oil & Gas Journal - MiMedx Group, Inc - Common Stock (Nasdaq:MDXG) Stock Quote
This article provides detailed stock information for MiMedx Group, Inc. (MDXG), including its current trading price, volume, historical performance, and recent news headlines. It also includes general information about Oil & Gas Journal, which hosts this stock quote data. The content highlights financial data, earnings reports, and market movements affecting MDXG.
MiMedx Group (MDXG) price target decreased by 18.75% to 6.63
This article reports that the price target for MiMedx Group (MDXG) has been decreased by 18.75%, bringing it down to $6.63. No additional details are provided in the current content.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP is investigating potential securities fraud claims against MiMedx Group, Inc. (MDXG) following a significant drop in its stock price. The investigation comes after MiMedx reported disappointing Q1 2026 financial results, missing consensus estimates for both earnings and revenue, and subsequently lowered its full-year 2026 net sales expectations due to new Medicare reimbursement policies affecting the wound care market. Investors who suffered losses are encouraged to contact the law firm.
Is the Options Market Predicting a Spike in MiMedx Group Stock?
The options market suggests a potential spike in MiMedx Group (MDXG) stock, with high implied volatility seen in its June 2026 $10 Call options. While options traders are pricing in a significant move, the fundamental analysis places MiMedx Group as a Zacks Rank #3 (Hold) with a recent downgrade in earnings estimates. This creates a scenario where options traders might sell premium, betting against a large price movement.
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Recommendation of "Moderate Buy" from Analysts
MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus "Moderate Buy" rating from seven covering firms, with an average 12-month price target of $8.50. Despite beating earnings expectations, the company's revenue fell short, and its stock was trading down 2.4% at $3.60. Institutional investors hold a significant 79.15% stake in the biopharmaceutical company.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX announced the commercial launch of G4Derm Plus, a new flowable biomimetic matrix that utilizes self-assembling peptide technology. This product, already available nationwide, expands MIMEDX's portfolio for surgical markets and is secured under Premier and Vizient GPO agreements. G4Derm Plus is designed for advanced wound management, promoting healthy tissue regrowth and acting as an antibacterial barrier.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX has launched G4Derm Plus, a new flowable biomimetic matrix that incorporates self-assembling peptide technology to aid in advanced wound management. The product, which is 510(k)-cleared, is already available to customers nationwide and is part of MIMEDX's strategy to expand its portfolio in surgical markets. G4Derm Plus is designed to support healthy tissue regrowth and act as an antibacterial barrier, and it is now accessible through Premier and Vizient GPO agreements.
MiMedx launches G4Derm Plus wound care product nationwide By Investing.com
MiMedx Group, Inc. has announced the nationwide commercial launch of G4Derm Plus, a novel wound management product utilizing self-assembling peptide technology. This launch aims to expand solutions for clinicians despite a recent 50% stock decline and first-quarter 2026 financial results that fell below expectations due to weak wound product sales and reimbursement changes.
MiMedx launches G4Derm Plus wound care product nationwide
MiMedx Group has commercially launched G4Derm Plus, a new wound management product, with initial sales already delivered across the U.S. This launch comes despite a recent 50% stock decline and the company missing Q1 2026 financial expectations, leading analysts to lower price targets. G4Derm Plus is a 510(k)-cleared flowable extracellular matrix leveraging self-assembling peptide technology for complex wound management.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX has commercially launched G4Derm Plus, an innovative flowable biomimetic matrix utilizing self-assembling peptide technology for advanced wound management. The product is 510(k)-cleared and is now available through major group purchasing organizations like Premier and Vizient. This launch expands MIMEDX's portfolio of solutions for surgical markets, aiming to provide clinicians with advanced regenerative therapies for complex wounds.
MIMEDX Announces Launch of G4Derm® Plus
MiMedx Group, Inc. (MIMEDX) has commercially launched G4Derm Plus, a flowable biomimetic matrix incorporating self-assembling peptide technology. This product, acquired by MIMEDX with exclusive U.S. distribution rights, is designed for advanced wound management and has already secured agreements with major group purchasing organizations like Premier and Vizient, facilitating national availability for clinicians. G4Derm Plus aims to support wound healing by encouraging tissue regrowth and providing an antibacterial barrier.
New wound-care matrix heads to hospitals via Premier, Vizient
MiMedx (Nasdaq: MDXG) has commercially launched G4Derm Plus, a 510(k)-cleared, acellular flowable extracellular matrix for advanced wound management. This new product, which uses self-assembling peptide technology, is now available nationwide through Premier and Vizient GPO agreements, expanding its reach into hospitals. The launch is part of MiMedx's strategy to broaden its surgical-focused product portfolio.
MiMedx Group (Nasdaq:MDXG) - Stock Analysis
This Simply Wall Street article provides a detailed stock analysis of MiMedx Group (MDXG), highlighting its current undervaluation by analysts despite projected earnings decline and recent revenue guidance cuts for 2026. The article covers past performance, recent news including Q1 2026 earnings misses and new product launches, insider transactions, and analyst price targets, indicating significant volatility and ongoing challenges in the wound care market and changes in Medicare reimbursement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP is investigating potential claims on behalf of investors of MiMedx Group, Inc. (MDXG) following a significant drop in its stock price. The investigation comes after MiMedx missed consensus estimates for its first-quarter 2026 financial results, with non-GAAP EPS and revenue falling short of expectations. The company attributed the poor performance to confusion caused by new Medicare reimbursement policies in the advanced wound care space, leading to a downward revision of its full-year 2026 net sales forecast.
U.S. Perinatal Tissue-derived Allograft Market Detailed In New Research Report 2026 | MIMEDX Group, Inc., Organogenesis, Inc.
The U.S. perinatal tissue-derived allograft market is projected to grow from USD 762.4 Mn in 2026 to USD 1,226.3 Mn by 2033, exhibiting a CAGR of 9.8%. A new research report by Coherent Market Insights details this growth, analyzing market dynamics, competitive landscapes, key investment pockets, and offering strategic insights for business leaders and investors. The report segments the market by product type, type, application, and end-user, profiling key players such as MIMEDX Group Inc. and Organogenesis Inc.
MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded MiMedx Group (NASDAQ:MDXG) from a "buy" to a "hold" rating, though the consensus among analysts remains a "Moderate Buy" with an average target of $8.50. Despite beating EPS estimates, the company missed revenue expectations for the last quarter. MiMedx stock opened higher after the earnings report, and institutional ownership remains high.
Q1 2026 MiMedx Group Inc Earnings Call Transcript
MiMedx Group Inc (MDXG) reported mixed results for Q1 2026, with strong 13% growth in its surgical business and a robust cash position of $142 million. However, the wound care business experienced a significant 60% decline due to changes in Medicare reimbursement policies, leading to an adjusted EBITDA loss of $12 million. The company is taking steps to address financial pressures, including a share repurchase program and a workforce reduction.
MiMedx Group (MDXG) Launches CHORIOFIX Placental Allograft for Complex, Tunneling Wounds
MiMedx Group Inc. (NASDAQ: MDXG) has commercially launched CHORIOFIX, a new placental allograft designed for complex and tunneling wounds. This product, featuring a unique triple-layer construction, is the thickest in their portfolio, enhancing handling for medical staff. CHORIOFIX is also being evaluated in the CAMPAIGN trial to assess its performance against standard care for diabetic foot ulcers.
MiMedx Group (MDXG) Q1 Loss And Margin Compression Test Bullish Growth Narratives
MiMedx Group (MDXG) reported a Q1 2026 loss of US$0.07 EPS and US$59.0 million in revenue, a significant drop from Q1 2025. This quarterly loss, coupled with a trailing net profit margin compression from 11.3% to 7.9%, challenges previous bullish narratives about the company's long-term growth and earnings potential. Despite a discounted cash flow (DCF) fair value higher than the current share price and analyst targets, investors are now evaluating how much of this margin pressure is already priced into the stock.
Medicare cuts hit MiMedx (NASDAQ: MDXG) as Q1 2026 sales fall
MiMedx Group (NASDAQ: MDXG) reported a significant decline in Q1 2026 net sales, falling 33.1% to $59.0 million, and consequently posted a net loss of $10.9 million compared to a profit in the prior year. This downturn was primarily attributed to new Medicare reimbursement changes for skin substitutes, which severely impacted its Wound segment sales, causing a 59.7% drop. Despite growth in its Surgical segment, the company initiated a cost reduction plan, including a 15% workforce reduction, to mitigate the financial impact.
Citizens cuts MiMedx stock price target to $6 on Medicare headwinds
Citizens has lowered its price target for MiMedx Group (NASDAQ:MDXG) to $6.00 from $7.00, citing ongoing 2026 Q1 operating challenges due to Medicare wound reimbursement changes. The stock is currently trading near its 52-week low as new payment processes, including pre-authorization requirements in some states, have negatively impacted sales and led to a cut in annual guidance.
MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results
MiMedx Group (NASDAQ:MDXG) reported Q1 adjusted EPS of ($0.05), beating estimates, but revenue of $58.99 million missed expectations due to a significant decrease in wound care sales. The company has implemented cost-saving measures, ended the quarter with substantial cash, and expects sequential recovery and profitability by Q3, with full-year adjusted EBITDA roughly breaking even. Despite the revenue miss and a 9% stock drop, analysts maintain a "Moderate Buy" rating with an average price target of $8.67.
MDXG Financials: Income Statement, Balance Sheet & Cash Flow | Mimedx Group Inc
This article provides a comprehensive overview of Mimedx Group Inc.'s (MDXG) financial statements, including its income statement, balance sheet, and cash flow, for fiscal year 2025 and previous periods. It highlights the company's strong financial health with high gross margins, increasing revenue, and a low debt-to-equity ratio. The analysis also covers profitability, growth, and liquidity metrics, along with an Altman Z-Score and Piotroski F-Score assessment.
Earnings call transcript: MiMedx Q1 2026 results miss forecasts, stock dips
MiMedx Group Inc. (MDXG) reported disappointing Q1 2026 results, missing both earnings and revenue forecasts, leading to a 1.76% stock price drop in aftermarket trading. The company posted an EPS of -$0.05 against an anticipated -$0.01 and revenue of $59 million, falling short of the $69.18 million expectation. This downturn is attributed primarily to significant disruptions in the wound care market due to Medicare reimbursement reforms, although the surgical business showed a 13% growth.
Form DEFA14A MIMEDX GROUP, INC.
MIMEDX GROUP, INC. has filed a definitive additional materials proxy statement (Form DEFA14A) with the United States Securities and Exchange Commission on April 29, 2026. This filing is pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicating an update to their proxy solicitation materials. No filing fee was required for this submission.
MiMedx (NASDAQ: MDXG) plans 2026 virtual meeting and key board, pay votes
MiMedx Group, Inc. (NASDAQ: MDXG) will hold its 2026 annual shareholder meeting virtually on June 10, 2026, where shareholders will vote on the election of seven directors, advisory approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The Board unanimously recommends all proposals. The proxy statement details MiMedx's strong 2025 financial performance, including 20% net sales growth and a 25% adjusted EBITDA margin, as well as its strategic initiatives and compensation practices designed to align executive interests with shareholder value.
Revenue drops as MiMedx (NASDAQ: MDXG) trims 2026 targets
MiMedx Group, Inc. reported a significant 33% drop in Q1 2026 net sales to $59 million, compared to $88 million in the prior year, largely due to new Medicare reimbursement rules severely impacting its Wound segment with a 60% decline. In response, the company has lowered its full-year 2026 net sales guidance to $260–$290 million and expects approximately breakeven Adjusted EBITDA. Despite the challenges, MiMedx's Surgical segment saw a 13% growth, and the company maintains healthy liquidity to navigate the market disruption.
MiMedx: Q1 Earnings Snapshot
MiMedx Group Inc. reported a Q1 loss of $10.9 million, or 7 cents per share, which adjusted to 5 cents per share after excluding non-recurring costs. The biomaterials developer generated $59 million in revenue for the period.
MiMedx Group Q1 2026 earnings preview
This article is a Q1 2026 earnings preview for MiMedx Group. As the provided content is only "MSN", no specific financial details or outlook can be summarized.
MiMedx Group (MDXG) price target decreased by 17.24% to 8.16
This article reports that the price target for MiMedx Group (MDXG) has been decreased by 17.24%, moving it to $8.16. The article does not provide further details on the reasons for this price target reduction.
Analyst Firms Lower MiMedx Price Targets Following Corporate Restructuring
Following a corporate restructuring and slow recovery in its wound care division, analysts at Northland and Craig-Hallum lowered their price targets for MiMedx Group Inc. Both firms, however, maintained optimistic ratings (Outperform and Buy, respectively) noting significant upside potential despite the reductions. MiMedx is implementing aggressive cost-cutting measures, including executive salary reductions and the elimination of the COO position, to stabilize its financial position after a drop in Medicare reimbursement.
Northland Reaffirms Outperform Rating for MiMedx Group (MDXG)
Northland has reaffirmed its Outperform rating for MiMedx Group (MDXG), despite reducing its price target from $10 to $6 due to a conservative outlook on the company's Wound Care business. The firm still sees significant upside potential (over 75%) and robust prospects for MiMedx's Surgical segment. This comes after Medicare reimbursement drops and a corporate restructuring, including $40 million in annual operating expense reductions.
Northland Reaffirms Outperform Rating for MiMedx Group (MDXG)
Northland has reaffirmed its Outperform rating for MiMedx Group (MDXG), despite reducing its price target from $10 to $6 due to a conservative stance on the company's Wound Care business near-term performance. The firm maintains a bullish outlook, supported by strong prospects in MiMedx's Surgical segment. Similarly, Craig-Hallum also lowered its price target but reiterated a Buy rating, noting the company's aggressive cost-cutting measures, including $40 million in annual operating expense reductions, after a slower-than-expected recovery in its core Wound Care division post-Medicare reimbursement changes.
MiMedx Group Launches Restructuring to Reduce Operating Costs
MiMedx Group, Inc. (NASDAQ:MDXG) has initiated a comprehensive restructuring program aimed at streamlining operations and reducing annual operating costs by approximately $40 million. This move comes as the company navigates a slow recovery and reimbursement challenges in the wound care sector. Citizens Financial Group lowered its price target for MDXG from $10 to $7 while maintaining an Outperform rating, reflecting the challenges despite the restructuring efforts.
Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends
Citizens Financial Group has lowered its price target for MiMedx Group, Inc. (MDXG) from $10 to $7, while maintaining an Outperform rating, due to slow recovery trends and reimbursement challenges in the wound care market despite the company's cost reduction efforts. MiMedx announced a restructuring program to streamline operations, including eliminating its COO role, with further details expected in its Q1 2026 earnings call. Although the firm holds a positive long-term view for MDXG, the article suggests that other AI stocks might offer more promising returns.
Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends
Citizens Financial Group has lowered its price target for MiMedx Group, Inc. (MDXG) from $10 to $7, citing sluggish recovery and reimbursement challenges in the wound care market, despite maintaining an "Outperform" rating. The company is implementing a restructuring program to reduce operating costs by approximately $40 million annually, which included eliminating the Chief Operating Officer role. Though near-term performance faces pressure, Citizens maintains a positive long-term outlook due to MDXG's strong clinical evidence and adaptability.
MiMedx Group (MDXG) to Release Earnings on Wednesday
MiMedx Group (MDXG) is set to release its Q1 2026 earnings after market close on Wednesday, April 29th, with analysts projecting an EPS of ($0.03) and revenue of $69.467 million. The company previously exceeded expectations in Q4 2025, reporting $0.14 EPS on $118.10 million in revenue. MDXG currently trades around $3.20, holds a "Moderate Buy" consensus rating with a target of $8.67, and has significant institutional ownership.
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
MIMEDX announced it will report its first quarter 2026 operating and financial results after market close on April 29, 2026. The company's senior management team will host a webcast and conference call at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be available on the MIMEDX website for approximately 30 days.
MIMEDX posts quarterly results April 29, with webcast after close
MiMedx Group, Inc. (Nasdaq: MDXG) announced that it will report its first-quarter 2026 operating and financial results after market close on Wednesday, April 29, 2026. The senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day. A replay of the webcast will be available for approximately 30 days on the company’s website.
MiMedx Group Is Maintained at Market Outperform by Citizens
Citizens has reiterated its "Market Outperform" rating for MiMedx Group. This indicates a continued positive outlook from the firm regarding the company's stock performance.
MiMedx launches restructuring to cut costs, refocus growth
MiMedx Group has initiated a restructuring and cost reduction program to prioritize growth, streamline operations, and lower expenses. This program includes eliminating the Chief Operating Officer role, reducing executive salaries, and is expected to generate $40 million in annualized savings. The company is responding to a sluggish recovery in its Wound Care business following a Medicare reimbursement reduction and aims to reallocate resources towards its growing Surgical business.
MiMedx Group (NasdaqCM:MDXG) Stock Forecast & Analyst Predictions
MiMedx Group (MDXG) is forecast to see a 20% decline in earnings per annum, while revenue is expected to grow by 2.9% annually. Analyst consensus EPS estimates have recently been downgraded. The company develops and commercializes human placental tissue products for wound care and surgical applications, with recent updates including executive changes, new product launches, and an equity buyback program.
MIMEDX Announces Restructuring and Cost Reduction Initiative
MiMedx Group, Inc. has announced a restructuring and cost reduction initiative aimed at prioritizing growth and streamlining operations. The company expects to achieve approximately $40 million in annualized savings and will incur a one-time restructuring charge of about $4 million in Q2 2026. This decision follows a detailed review of their business, specifically noting the slow recovery of the Wound Care business after a Medicare reimbursement reduction.
MiMedx Group reduces executive pay, eliminates COO role
MiMedx Group (NASDAQ: MDXG) announced a cost reduction initiative on April 14, 2026, which included eliminating the chief operating officer position and reducing executive compensation. Ricci Whitlow departed as COO, and the CEO's base salary was cut by 20%, while other senior executives saw a 10% reduction. These measures are intended to prioritize growth, streamline operations, and decrease operating expenses through December 31, 2026.
MiMedx Group, Inc. Announces Departure of Ricci Whitlow as Chief Operating Officer, Effective April 14, 2026
MiMedx Group, Inc. announced the departure of Ricci Whitlow as Chief Operating Officer, effective April 14, 2026. This change is part of a cost-reduction initiative aimed at prioritizing growth, streamlining operations, and significantly reducing operating expenses. Ms. Whitlow's departure was not due to a disagreement with the company.
